This study is in progress, not accepting new patients
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSF
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Deciphera Pharmaceuticals LLC
- ID
- NCT03717415
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 117 study participants
- Last Updated